Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold. IGNITE DMD is designed to assess the safety and efficacy of SGT-001 in ambulatory and non-ambulatory children and adolescents with DMD. The first patient dosed in the clinical trial was a non-ambulatory adolescent who received 5E13 vg/kg of SGT-001 on February 14, 2018. Several days after administration the patient was hospitalized due to laboratory findings that included a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation. The patient showed no signs or symptoms of coagulopathy (bleeding disorder) and no relevant changes from baseline in liver function tests. The patient responded
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumGlobeNewswire
- Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Barclays PLC from $8.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
SLDB
Earnings
- 11/8/23 - Beat
SLDB
Sec Filings
- 3/13/24 - Form S-3
- 3/13/24 - Form S-8
- 3/13/24 - Form 10-K
- SLDB's page on the SEC website